Loading…
Omeros Corporation is projected to rise to $14.81 by 2027, a +44% move from its current price of $10.28. OMER is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $9.77 | $10.29 | $10.83 | +0.07% |
| Jul 14 | $9.57 | $10.29 | $11.07 | +0.14% |
| Jul 15 | $9.42 | $10.30 | $11.26 | +0.21% |
| Jul 16 | $9.30 | $10.31 | $11.43 | +0.28% |
| Jul 17 | $9.19 | $10.32 | $11.58 | +0.36% |
| Jul 18 | $9.10 | $10.32 | $11.71 | +0.43% |
| Jul 19 | $9.01 | $10.33 | $11.84 | +0.50% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.01 | $10.33 | $11.84 | +0.50% |
| Week 2 | $8.56 | $10.38 | $12.59 | +1.00% |
| Week 3 | $8.24 | $10.43 | $13.21 | +1.50% |
| Week 4 | $7.98 | $10.49 | $13.77 | +2.01% |
| Week 5 | $7.77 | $10.54 | $14.29 | +2.51% |
| Week 6 | $7.58 | $10.59 | $14.79 | +3.02% |
| Week 7 | $7.42 | $10.64 | $15.27 | +3.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Omeros Corporation is a healthcare company described as a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. Its lead products candidate is Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. The company also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder.
In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Omeros Corporation operates in the Healthcare sector as a biopharmaceutical company focused on immunologic diseases. It is currently trading with a price of $9.91 per share and a market capitalization of $717.24M, ranking it at 2655 by market size. The current price sits in a complex, single-name biotech space where forward-looking forecasts accompany the equity’s exposure to clinical development risk.
A major floor 26.5% below — a decisive break under it would weaken the trend.
The nearest floor, 15.7% below — buyers have tended to step in here.
The nearest ceiling, 8.5% above — a clean break opens room to run.
A major ceiling 46.5% above — clearing it would confirm fresh momentum.
Key OMER support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OMER market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.29 | Sell | $10.18 | Buy |
| MA 10 | $9.82 | Buy | $10.07 | Buy |
| MA 20 | $9.90 | Buy | $10.14 | Buy |
| MA 50 | $11.40 | Sell | $10.80 | Sell |
| MA 100 | $11.57 | Sell | $11.04 | Sell |
| MA 200 | $10.52 | Sell | $10.27 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.71 | Neutral |
| Stoch RSI (14) | 97.27 | Sell |
| CCI (20) | 49.29 | Neutral |
| Williams %R (14) | -21.46 | Info |
| MACD (12,26,9) | 0.16 | Buy |
| ROC (12) | -1.91 | Sell |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 78.54 | Neutral |
| TRIX (15) | -0.56 | Sell |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 64.86 | Neutral |
| Momentum (10) | -0.44 | Sell |
| Aroon Osc (25) | -4.00 | Sell |
| Hull MA (9) | 10.49 | Sell |
| ADX (14) | 16.12 | Neutral |
| ATR (14) | 0.36 | Info |
Technically, the stock has a NEUTRAL near-term posture with RSI(14) at 40. Its 50-day simple moving average sits at $12.01, above the 200-day average of $10.28, suggesting a mixed longer-term trend. The stock shows a defined near-term support at $8.67 and resistance at $12.38, framing a plausible 30-day range from $6.66 to $14.75.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.67 | $10.28 | $15.95 | 0% | Neutral | |
| $10.82 | $14.81 | $21.89 | +44% | Bullish | |
| $9.48 | $13.76 | $21.64 | +34% | Bullish | |
| $9.46 | $14.43 | $23.80 | +40% | Bullish | |
| $9.89 | $15.77 | $27.05 | +53% | Bullish | |
| $8.16 | $13.57 | $24.07 | +32% | Bullish | |
| $9.87 | $17.09 | $31.25 | +66% | Bullish | |
| $12.62 | $22.71 | $42.64 | +121% | Bullish | |
| $12.80 | $23.89 | $45.98 | +132% | Bullish | |
| $13.90 | $26.92 | $52.98 | +162% | Bullish | |
| $15.94 | $35.43 | $76.50 | +245% | Bullish | |
| $26.84 | $59.65 | $137.20 | +480% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $8.67 | $10.28 | $12.19 | +0.00% |
| August 2026 | $8.59 | $10.38 | $13.06 | +1.02% |
| September 2026 | $8.95 | $10.97 | $14.08 | +5.61% |
| October 2026 | $8.73 | $10.82 | $14.12 | -1.34% |
| November 2026 | $8.76 | $10.98 | $14.53 | +1.45% |
| December 2026 | $9.41 | $11.90 | $15.95 | +8.40% |
Click any year to see its month-by-month OMER forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The OMER price prediction for 2026 points to an average of $10.28 (low $8.67, high $15.95) — a potential gain of 0% on today's $10.28. Price action looks broadly range-bound.
In 2027, OMER is projected to trade between $10.82 and $21.89, averaging $14.81 — a potential gain of +44% from today's $10.28. That is up +44% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Omeros Corporation's 2028 outlook centres on $13.76, within a $9.48 to $21.64 range. That is -7% versus the projected 2027 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2029, OMER could reach as high as $23.80, with a base case around $14.43 and support toward $9.46 — roughly +40% from $10.28. Buyers look set to stay in control over this stretch.
Expect OMER to range from $9.89 to $27.05 through 2030. The $15.77 average target implies a +53% move from current prices. That is up +9% on the projected 2029 average. Momentum favours further upside here.
The OMER price prediction for 2031 points to an average of $13.57 (low $8.16, high $24.07) — a potential gain of +32% on today's $10.28. Buyers look set to stay in control over this stretch.
In 2032, OMER is projected to trade between $9.87 and $31.25, averaging $17.09 — a potential gain of +66% from today's $10.28. That is up +26% on the projected 2031 average. Momentum favours further upside here.
Omeros Corporation's 2033 outlook centres on $22.71, within a $12.62 to $42.64 range. That is up +33% on the projected 2032 average. That marks a +121% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, OMER could reach as high as $45.98, with a base case around $23.89 and support toward $12.80 — roughly +132% from $10.28. Momentum favours further upside here.
Expect OMER to range from $13.90 to $52.98 through 2035. The $26.92 average target implies a +162% move from current prices. That is up +13% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The OMER price prediction for 2040 points to an average of $35.43 (low $15.94, high $76.50) — a potential gain of +245% on today's $10.28. Momentum favours further upside here.
In 2050, OMER is projected to trade between $26.84 and $137.20, averaging $59.65 — a potential gain of +480% from today's $10.28. That is up +68% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in OMER today (≈ 97.276265 OMER) could be worth
$5,802.93
+$4,802.93 (+480%) by 2050 · US Dollar
Based on the average projected OMER price of $59.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OMERwould be worth at today's price.
$1,000 invested in OMER on Jul 10, 2025 (≈ 289.017338 OMER) would be worth
$2,971.1
+$1,971.1 (+197.1%) today · 2.97× · US Dollar
Based on a OMER entry price of $3.46 vs. today's $10.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.28 | $1,107.76 | +10.8% |
| 1 month ago | $10.2 | $1,007.84 | +0.8% |
| 3 months ago | $11.49 | $894.69 | -10.5% |
| 6 months ago | $12.82 | $801.87 | -19.8% |
| 1 year ago | $3.46 | $2,971.1 | +197.1% |
| All time (5.0y) ago | $14.27 | $720.39 | -28.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OMER forecast.
Our base-case forecast reaches $21.00 around 2033.
Implied market cap at $21.00: $1.52B
The multi-year forecast paints a bullish trajectory beyond 2026, with the 2026 average price at $9.91 and a 30-day view range between $8.67 and $16.02. Beyond 2026, the model projects higher averages and rising ROI, peaking by 2050 with an average price of $56.28 and a maximum of $129.44, accompanied by a 467.9 ROI (broadly bullish sentiment for the long horizon). Notable yearly marks include 2027 avg $14.16 (ROI 42.9), 2028 avg $13.55 (ROI 36.7), 2029 avg $14.09 (ROI 42.1), 2030 avg $14.79 (ROI 49.3), 2031 avg $12.82 (ROI 29.3), 2032 avg $16.30 (ROI 64.5), 2033 avg $21.76 (ROI 119.5), 2034 avg $23.31 (ROI 135.2), 2035 avg $25.89 (ROI 161.3), 2040 avg $34.12 (ROI 244.3).
These figures imply a steady lift in mid-to-long term price with substantial upside relative to the 2026 baseline. Companies operating in this space face significant uncertainty; these figures are estimates, not guarantees, and should be interpreted with caution given clinical, regulatory, and market risks.
Tap a question to reveal the answer.
According to the forecast, the 2030 average price is $14.79 with a 2030 min of $9.13 and a max of $25.70, and a projected ROI of 49.3 alongside a bullish sentiment.
The forecast shows a long-run bullish trend from 2027 through 2050 with rising average prices and ROI peaks, though the 2026 baseline is $9.91 with a 0 ROI. These are estimates and not guarantees; always consider risk related to clinical-stage biopharmaceuticals.
The forecast max by 2050 is $129.44, indicating potential upside to and beyond $100 under the projection, but these are not guaranteed outcomes and depend on various factors.
The current price is $9.91 and the market cap is $717.24M.
The 30-day range spans $6.66 to $14.75, with near-term support at $8.67 and resistance at $12.38. RSI(14) is 40, SMA50 is $12.01, and SMA200 is $10.28.
Omeros Corporation Community Discussion
0Share your Omeros Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.